## Amy C Degnim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3498292/publications.pdf

Version: 2024-02-01

142 papers 6,334 citations

71102 41 h-index 76900 74 g-index

148 all docs 148
docs citations

148 times ranked 5709 citing authors

#	Article	IF	CITATIONS
1	Benign Breast Disease and the Risk of Breast Cancer. New England Journal of Medicine, 2005, 353, 229-237.	27.0	785
2	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific Reports, 2016, 6, 30751.	3.3	299
3	Atypical Hyperplasia of the Breast â€" Risk Assessment and Management Options. New England Journal of Medicine, 2015, 372, 78-89.	27.0	281
4	Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study. Journal of Clinical Oncology, 2007, 25, 2671-2677.	1.6	226
5	Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. American Journal of Surgery, 2005, 190, 543-550.	1.8	223
6	Age-Related Lobular Involution and Risk of Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1600-1607.	6.3	218
7	Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study. Cancer Prevention Research, 2014, 7, 211-217.	1.5	192
8	Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer, 2003, 98, 2307-2315.	4.1	145
9	Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With <i>BRCA</i> Mutations. JAMA Surgery, 2018, 153, 123.	4.3	140
10	Society of Surgical Oncology: Position Statement on Prophylactic Mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Annals of Surgical Oncology, 2007, 14, 2425-2427.	1.5	119
11	Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node. Annals of Surgery, 2012, 255, 109-115.	4.2	116
12	Reasons for Re-Excision After Lumpectomy for Breast Cancer: Insight from the American Society of Breast Surgeons MasterySM Database. Annals of Surgical Oncology, 2014, 21, 3185-3191.	1.5	104
13	Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2010, 28, 3591-3596.	1.6	103
14	Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2008, 26, 5374-5379.	1.6	94
15	Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: Evaluation of the National Surgical Quality Improvement Program data. Surgery, 2014, 156, 190-197.	1.9	90
16	Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer, 2015, 121, 1548-1555.	4.1	85
17	Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Research and Treatment, 2008, 108, 167-174.	2.5	83
18	Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. American Journal of Surgery, 2008, 196, 228-233.	1.8	76

#	Article	IF	CITATIONS
19	Cost-Effectiveness Analysis of Routine Frozen-Section Analysis of Breast Margins Compared with Reoperation for Positive Margins. Annals of Surgical Oncology, 2011, 18, 3204-3209.	1.5	74
20	Sclerosing adenosis and risk of breast cancer. Breast Cancer Research and Treatment, 2014, 144, 205-212.	2.5	72
21	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2017, 164, 295-304.	2.5	68
22	Sentinel lymph node biopsy for breast cancer: How many nodes are enough?. Journal of Surgical Oncology, 2007, 96, 554-559.	1.7	67
23	Terminal Duct Lobular Unit Involution of the Normal Breast: Implications for Breast Cancer Etiology. Journal of the National Cancer Institute, 2014, 106, .	6.3	67
24	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Research and Treatment, 2014, 144, 539-549.	2.5	65
25	Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Research and Treatment, 2012, 133, 169-177.	2.5	64
26	Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Research and Treatment, 2010, 121, 431-437.	2.5	63
27	Randomized Controlled Trial to Reduce Bacterial Colonization of Surgical Drains After Breast and Axillary Operations. Annals of Surgery, 2013, 258, 240-247.	4.2	63
28	Postoperative Prophylactic Antibiotics and Surgical Site Infection Rates in Breast Surgery Patients. Annals of Surgical Oncology, 2009, 16, 2464-2469.	1.5	58
29	Incidence of Clinically Significant Seroma after Breast and Axillary Surgery. Journal of the American College of Surgeons, 2009, 208, 148-150.	0.5	56
30	Clinicopathologic Features Associated With Having Four or More Metastatic Axillary Nodes in Breast Cancer Patients With a Positive Sentinel Lymph Node. Annals of Surgical Oncology, 2006, 13, 36-44.	1.5	55
31	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2596-2602.	1.5	55
32	Pseudoangiomatous Stromal Hyperplasia and Breast Cancer Risk. Annals of Surgical Oncology, 2010, 17, 3269-3277.	1.5	52
33	Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy. Journal of Clinical Oncology, 2015, 33, 923-929.	1.6	51
34	Macrophagic "Crown-like Structures―Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. Cancer Prevention Research, 2018, 11, 113-119.	1.5	50
35	Risk Factors Associated with Breast Lymphedema. Annals of Surgical Oncology, 2014, 21, 1202-1208.	1.5	48
36	Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case–control study. Breast Cancer Research and Treatment, 2016, 159, 163-172.	2.5	48

#	Article	IF	CITATIONS
37	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer, 2016, 122, 2971-2978.	4.1	48
38	A prospective study of breast lymphedema: frequency, symptoms, and quality of life. Breast Cancer Research and Treatment, 2012, 134, 915-922.	2.5	47
39	A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. Annals of Surgical Oncology, 2017, 24, 2915-2924.	1.5	47
40	Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women. Plastic and Reconstructive Surgery - Global Open, 2019, 7, e2119.	0.6	47
41	Surgical Site Infection after Breast Surgery: Impact of 2010 CDC Reporting Guidelines. Annals of Surgical Oncology, 2012, 19, 4099-4103.	1.5	46
42	Surgical Management of High-Risk Breast Lesions. Surgical Clinics of North America, 2013, 93, 329-340.	1.5	46
43	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clinical Cancer Research, 2017, 23, 3945-3952.	7.0	46
44	Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 3549-3558.	1.5	46
45	Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Research and Treatment, 2007, 102, 137-142.	2.5	44
46	Novel Breast Tissue Feature Strongly Associated With Risk of Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5893-5898.	1.6	44
47	Introducing the SKIN Score: A Validated Scoring System to Assess Severity of Mastectomy Skin Flap Necrosis. Annals of Surgical Oncology, 2015, 22, 2925-2932.	1.5	42
48	Prepectoral Two-Stage Implant-Based Breast Reconstruction with and without Acellular Dermal Matrix: Do We See a Difference?. Plastic and Reconstructive Surgery, 2020, 145, 263e-272e.	1.4	41
49	Single-Stage Direct-to-Implant Breast Reconstruction. Annals of Plastic Surgery, 2020, 84, 361-365.	0.9	40
50	A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 999-1012.	3.0	39
51	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. Surgery, 2016, 159, 1199-1209.	1.9	39
52	Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. BMC Genomics, 2019, 20, 689.	2.8	37
53	National Practice Patterns in Preoperative and Postoperative Antibiotic Prophylaxis in Breast Procedures Requiring Drains: Survey of the American Society of Breast Surgeons. Annals of Surgical Oncology, 2012, 19, 3205-3211.	1.5	36
54	Aurora-A kinase oncogenic signaling mediates TGF-Î <sup>2</sup> -induced triple-negative breast cancer plasticity and chemoresistance. Oncogene, 2021, 40, 2509-2523.	5.9	34

#	Article	IF	Citations
55	Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different?. Surgery, 2008, 143, 641-647.	1.9	31
56	Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph nodeâ€positive breast cancer patients. Cancer, 2009, 115, 4064-4070.	4.1	31
57	Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer, 2016, 122, 378-385.	4.1	31
58	Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. Surgery, 2019, 166, 709-714.	1.9	30
59	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells. PLoS ONE, 2014, 9, e96995.	2.5	30
60	Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely $\hat{A}^{\otimes}$ Initiative. Annals of Surgical Oncology, 2016, 23, 3112-3118.	1.5	29
61	Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Research and Treatment, 2016, 155, 423-430.	2.5	29
62	Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases. Human Pathology, 2016, 49, 33-38.	2.0	29
63	Pure Tubular Carcinoma and Axillary Nodal Metastases. Annals of Surgical Oncology, 2010, 17, 338-342.	1.5	27
64	The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as Long as All Disease is Confined to the Sentinel Lymph Nodes. Annals of Surgical Oncology, 2011, 18, 86-93.	1.5	26
65	Lobular Neoplasia and Atypical Ductal Hyperplasia on Core Biopsy: Current Surgical Management Recommendations. Annals of Surgical Oncology, 2017, 24, 2848-2854.	1.5	26
66	Challenging Atypical Breast Lesions Including Flat Epithelial Atypia, Radial Scar, and Intraductal Papilloma. Annals of Surgical Oncology, 2017, 24, 2842-2847.	1.5	26
67	Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. Annals of Surgical Oncology, 2019, 26, 3115-3123.	1.5	26
68	Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. Annals of Surgical Oncology, 2016, 23, 465-470.	1.5	25
69	Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. Plastic and Reconstructive Surgery, 2019, 144, 1270-1277.	1.4	25
70	Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Research, 2017, 19, 134.	5.0	24
71	Microbiology of Surgical Site Infections Complicating Breast Surgery. Surgical Infections, 2010, 11, 355-359.	1.4	23
72	Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer, 2017, 17, 84.	2.6	23

#	Article	IF	Citations
73	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget, 2017, 8, 91803-91816.	1.8	23
74	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	1.6	22
75	Workload Differentiates Breast Surgical Procedures: NSM Associated with Higher Workload Demand than SSM. Annals of Surgical Oncology, 2020, 27, 1318-1326.	1.5	22
76	Complications associated with postoperative antibiotic prophylaxis after breast surgery. American Journal of Surgery, 2009, 198, 553-556.	1.8	21
77	Axillary Recurrence in Breast Cancer Patients with Isolated Tumor Cells in the Sentinel Lymph Node [AJCC NO(i+)]. Annals of Surgical Oncology, 2010, 17, 2685-2689.	1.5	21
78	Lobular involution: localized phenomenon or field effect?. Breast Cancer Research and Treatment, 2009, 117, 193-196.	2.5	20
79	Breast cancer-related paraneoplastic neurologic disease. Breast Cancer Research and Treatment, 2018, 167, 771-778.	2.5	20
80	Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram?. Annals of Surgical Oncology, 2005, 12, 712-717.	1.5	19
81	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical Breast Cancer, 2018, 18, e501-e506.	2.4	19
82	Should Re-excision Lumpectomy Rates Be a Quality Measure in Breast-Conserving Surgery?. Annals of Surgical Oncology, 2013, 20, 3180-3183.	1.5	18
83	Diffuse dermal angiomatosis of the breast: a series of 22 cases from a single institution. Gland Surgery, 2015, 4, 554-60.	1.1	17
84	$\rm ER\hat{l}^2$ Expression and Breast Cancer Risk Prediction for Women with Atypias. Cancer Prevention Research, 2015, 8, 1084-1092.	1.5	16
85	When Does Atypical Ductal Hyperplasia Require Surgical Excision?. Surgical Oncology Clinics of North America, 2018, 27, 23-32.	1.5	16
86	The American Society of Breast Surgeons and Quality Payment Programs: Ranking, Defining, and Benchmarking More Than 1 Million Patient Quality Measure Encounters. Annals of Surgical Oncology, 2017, 24, 3093-3106.	1.5	15
87	Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2020, 27, 5303-5311.	1.5	15
88	Uncommon Benign Breast Abnormalities in Adolescents. Seminars in Plastic Surgery, 2013, 27, 026-028.	2.1	14
89	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. Annals of Surgical Oncology, 2016, 23, 72-77.	1.5	14
90	Margin Proximity Correlates with Local Recurrence After Mastectomy for Patients Not Receiving Adjuvant Radiotherapy. Annals of Surgical Oncology, 2017, 24, 3148-3156.	1.5	14

#	Article	IF	CITATIONS
91	Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® Campaign. Annals of Surgical Oncology, 2018, 25, 2795-2800.	1.5	14
92	Randomized Trial of Drain Antisepsis After Mastectomy and Immediate Prosthetic Breast Reconstruction. Annals of Surgical Oncology, 2014, 21, 3240-3248.	1.5	13
93	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clinical Cancer Research, 2020, 26, 1045-1053.	7.0	13
94	A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3297-3303.	1.5	12
95	Gene signature model for breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Research and Treatment, 2015, 152, 687-694.	2.5	11
96	Cellular fibroepithelial lesions of the breast: A long term follow up study. Annals of Diagnostic Pathology, 2018, 35, 85-91.	1.3	11
97	Two-Staged Implant-Based Breast Reconstruction: A Long-Term Outcome Study in a Young Population. Medicina (Lithuania), 2019, 55, 481.	2.0	11
98	Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Research, 2019, 21, 38.	5.0	11
99	Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. Cancer Prevention Research, 2021, 14, 175-184.	1.5	11
100	Breast Cancer Presenting as Unilateral Arm Edema. Journal of General Internal Medicine, 2007, 22, 675-676.	2.6	10
101	Breast cancer risk by the extent and type of atypical hyperplasia. Cancer, 2016, 122, 3087-3088.	4.1	10
102	Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies. Journal of the National Cancer Institute, 2017, 109, .	6.3	10
103	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Research and Treatment, 2017, 166, 641-650.	2.5	10
104	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. American Journal of Surgery, 2017, 213, 810-813.	1.8	9
105	Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. Cancer Prevention Research, 2020, 13, 967-976.	1.5	9
106	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery, 2021, 169, 644-648.	1.9	9
107	The breast tissue microbiome, stroma, immune cells and breast cancer. Neoplasia, 2022, 27, 100786.	5.3	9
108	Should axillary ultrasound be used in patients with a preoperative diagnosis of ductal carcinoma in situ?. American Journal of Surgery, 2012, 204, 290-293.	1.8	8

#	Article	IF	CITATIONS
109	Contemporary operative management of T4 breast cancer. Surgery, 2016, 160, 1059-1069.	1.9	8
110	Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters. Annals of Surgical Oncology, 2018, 25, 501-511.	1.5	8
111	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3365-3370.	1.5	7
112	Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer, 2018, 124, 3319-3328.	4.1	7
113	Simple Prediction Models for Breast Cancer Patients with Solitary Positive Sentinel Nodes-are they Valid?. Breast Journal, 2009, 15, 610-614.	1.0	6
114	Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. Brachytherapy, 2016, 15, 796-803.	0.5	6
115	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 8729-8739.	1.5	6
116	Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning. Npj Breast Cancer, 2022, 8, 13.	5.2	6
117	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Research and Treatment, 2018, 167, 649-658.	2.5	5
118	Breast Reconstruction in the Setting of Stage 4 Breast Cancer: Is It Worthwhile?. Annals of Surgical Oncology, 2020, 27, 4730-4739.	1.5	5
119	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. Breast Cancer Research and Treatment, 2020, 180, 55-61.	2.5	4
120	Predicting Four or More Metastatic Axillary Lymph Nodes in Patients with Sentinel Node-Positive Breast Cancer: Assessment of Existent Risk Scores. Annals of Surgical Oncology, 2010, 17, 2884-2891.	1.5	3
121	A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection. Annals of Surgical Oncology, 2016, 23, 3494-3500.	1.5	3
122	Dense Breasts: What Do Our Patients Need to Be Told and Why?. Annals of Surgical Oncology, 2016, 23, 3119-3127.	1.5	3
123	Breast Atypia as a Biomarker of Risk. Current Breast Cancer Reports, 2019, 11, 95-99.	1.0	3
124	Bioimpedance Spectroscopy of the Breast. Lymphatic Research and Biology, 2020, 18, 448-454.	1,1	3
125	Primary tumor resection in patients with stage IV breast cancer: 10â€year experience. Breast Journal, 2021, 27, 863-871.	1.0	3
126	Sentinel lymph node biopsy for breast cancer: is two-site injection best?. Surgery, 2006, 139, 630-632.	1.9	2

#	Article	IF	CITATIONS
127	Somatic mutations in benign breast disease tissues and association with breast cancer risk. BMC Medical Genomics, 2021, 14, 185.	1.5	2
128	Refining risk assessment in women with atypical hyperplasia. Current Breast Cancer Reports, 2009, 1, 167-174.	1.0	1
129	An unusual presentation of breast cancer in a very young woman. BMJ Case Reports, 2011, 2011, bcr1220103590-bcr1220103590.	0.5	1
130	Risk Factors for Breast Carcinoma in Women With Proliferative Breast Disease., 2018,, 264-271.e2.		1
131	Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation. Modern Pathology, 2019, 32, 1263-1270.	5.5	1
132	Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Riskâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 797-797.	2.5	1
133	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 560-561.	1.5	1
134	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, 29, 4167-4179.	1.5	1
135	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence. Breast Cancer Research, 2022, 24, .	5.0	1
136	Reply to S.L. Gomez et al. Journal of Clinical Oncology, 2010, 28, e158-e158.	1.6	0
137	Infections after breast surgery: potential ways to reduce infection rates. Breast Cancer Management, 2015, 4, 17-24.	0.2	0
138	Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution. Breast Cancer Research and Treatment, 2017, 166, 133-143.	2.5	0
139	Prophylactic Mastectomy in Patients with Atypical Breast Lesions. , 2018, , 147-157.		0
140	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, , .	1.5	0
141	Serum hormone levels and normal breast histology among premenopausal women. Breast Cancer Research and Treatment, 2022, , .	2.5	0
142	The Benefits of Local Anesthesia Used in Mastectomy Without Reconstruction. American Surgeon, 0, , 000313482210919.	0.8	0